NCT02932878View on ClinicalTrials.gov

An Open Label, Safety Study to Assess the Potential for Adrenal Suppression

PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

September 2, 2016

Primary Completion Date

April 10, 2017

Study Completion Date

October 16, 2017

Conditions
Plaque Psoriasis
Interventions
DRUG

DSXS topical

topical treatment

Trial Locations (1)

10532

Taro Pharmaceuticals USA Inc., Hawthorne

All Listed Sponsors
lead

Sun Pharmaceutical Industries, Inc.

INDUSTRY

NCT02932878 - An Open Label, Safety Study to Assess the Potential for Adrenal Suppression | Biotech Hunter | Biotech Hunter